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Background: The purpose of this study is to investigate the most suitable first-line approach and the best
combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of
debate for at least two decades.
Methods: Our single centre experience in the treatment of 98 de novo PMLBCL patients over the last 20 years is
reviewed. All patients received MACOP-B chemotherapy. Thirty-seven received both rituximab and mediastinal
radiotherapy; 30 were irradiated after chemotherapy, although not receiving rituximab and 20 received rituximab
without radiotherapy consolidation. Eleven patients received chemotherapy only.
Results: Sixty-one (62.2%) patients achieved a complete response after MACOP-B (with or without rituximab);
among the 27 (27.6%) partial responders, 21 obtained a complete response after radiotherapy. At the end of their
scheduled treatment, 82 patients (83.7%) had a complete and 6 a partial response (6.1%). Eleven patients relapsed
within the first 2 years of follow-up. The 17-year overall survival is 72.0% (15 patients died); progression-free and
disease-free survival are 67.6% and 88.4%, respectively. A statistically significant difference in overall and progression-
free survival was noted among treatment groups, although no disease-free survival difference was documented.
Conclusions: Our data indicate that a third-generation regimen like MACOP-B could be considered a suitable first-line
treatment. Mediastinal consolidation radiotherapy impacts on survival and complete response rates and remains a
good strategy to convert partial into complete responses. Data suggest that radiotherapy may be avoided in patients
obtaining a complete response after (immuno)chemotherapy, but this requires confirmation with further ad hoc
studies.
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The 1994 Revised European American Lymphoma (REAL)
Classification firstly recognizes primary mediastinal large
B-cell lymphoma (PMLBCL) as a subtype of diffuse large
B-cell lymphoma (DLBCL), although it has been regarded
as a specific clinical and biological entity since the 2001
World Health Organization classification [1, 2].
It is a rapidly-growing and progressive neoplasm, nor-
mally presenting with bulky masses usually exerting
compressive effects on mediastinal structures, giving rise* Correspondence: alessandro.broccoli@studio.unibo.it
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acic pain, facial, neck, breasts and arms edema and
pleuro-pericardial effusions. In this sense, it should be
regarded as a hematological emergency, and promptly
treated: initial therapy is therefore crucial for the man-
agement of this disease.
In the last 15 years, several issues have emerged re-
garding the treatment of this disease, and in particular:
1) the choice of initial chemotherapy approach, based on
either CHOP (cyclophosphamide, doxorubicin, vincris-
tine and prednisone) and CHOP-like schedules or more
intense ones, such as the so-called “third-generation”
regimens, perhaps including a high-dose consolidationle is distributed under the terms of the Creative Commons Attribution 4.0
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[3]; 2) the value of a rituximab-based immunotherapy in
this subset of patients, on the basis of the results ob-
tained in randomized studies involving DLBCL patients
[4, 5]; 3) the role of external beam radiotherapy (RT), as
an adjuvant strategy through which consolidate a re-
sponse to chemotherapy and produce an eradication of
the disease [6].
In terms of first-line chemotherapy, if on the one hand
the CHOP regimen has been mainly adopted by Ameri-
can centers, the European experience has carried out the
evidence that MACOP-B (methotrexate, doxorubicin,
cyclophosphamide, vincristine, bleomycin, prednisone)
or VACOP-B (same as MACOP-B, with etoposide in-
stead of methotrexate), both weekly-based “third-gener-
ation” dose-dense regimens, may be superior to CHOP
[7–9]. As a consequence of the application of dose-
dense regimens, in fact, remission rates and survival
functions have appeared to be at least as good as – or
probably even better than – those observed for DLBCL
patients, thus retracting the initial impression that
PMLBCL was per se a prognostically unfavorable subset
of DLBCL. Although this conclusion is drawn from
existing reports, no randomized clinical trial have been
carried on so far. It is clear, however, that an
anthracycline-containing regimen should be regarded as
the first approach to PMBCL [10].
The addition of rituximab to first line chemotherapy
has shown no advantages in terms of overall and
relapse-free survival if the monoclonal antibody was
added to a third-generation regimen [11], although R-
CHOP chemoimmunotherapy seems significantly super-
ior to CHOP alone [12, 13].
External RT, conceived as the delivery of radiation on
residues of bulky masses at the end of chemotherapy,
has shown a great efficacy when it was incorporated
after the completion of an induction strategy based on
chemotherapy, particularly in converting partial re-
sponses into complete responses and in rendering active
residual masses negative at gallium scan or positron
emission tomography (PET) [14–16].
This report presents our 20 years monocentric experi-
ence in the first-line treatment of primary mediastinal
patients, in accordance with our Institute treatment pol-
icy and with the practical guidelines outlined by the Ital-
ian Society of Hematology [10].
Methods
To perform this population-based retrospective study,
our clinical database was searched to find all the con-
secutive patients with a diagnosis of PMLBCL, homoge-
neously treated with a third-generation MACOP-B
chemotherapy regimen, regardless they received either
chemotherapy alone, immunotherapy, consolidative RT,or a combination of all these strategies. Patients treated
with chemotherapy regimens other than MACOP-B
were excluded. The study was approved by our institu-
tional board and by our Ethical Committee and has been
performed in accordance with the ethical standards as
laid down in the 1964 Declaration of Helsinki and its
later amendments. Patients were consecutively enrolled
to avoid selection bias, and all patients provided written
informed consent to collect retrospectively their data.
We obtained a special permission (for scientific purpose)
from our Ethical Committee to collect even data of pa-
tients who were deceased or lost to follow up.
Diagnostic and staging procedures
Between October 1989 and April 2010, 98 patients with
de novo PMLBCL were diagnosed and subsequently
treated in our Institution. Diagnostic material was ob-
tained by supraclavicular or transthoracic lymph node
biopsy, thoracotomy or mediastinoscopy. Initial clinical
evaluation included physical examination, hematologic
and biochemical survey, chest X-ray, computed tomog-
raphy (CT) scan of neck, chest, abdomen and pelvis, and
unilateral bone marrow biopsy. PET scan was also per-
formed at baseline in all patients treated after 2001.
Disease stage was established according to the Ann
Arbor staging system. Stage II indicated disease spread
within contiguous thoracic, jugular or supraclavicular
nodes, whereas the presence of distant, non-contiguous,
involved nodes on both sides of the diaphragm was con-
sistent with stage III. Patients with any extranodal
involvement apart from mediastinal disease were catego-
rized as stage IV. The extent of mediastinal disease was
defined as mediastinal mass ratio (MMR), which was
calculated by measuring the maximum single horizontal
width of the mass on a standing chest radiograph, and
dividing it by the maximum intrathoracic diameter. An
MMR exceeding one third or a mass measuring more
than 10 cm in its largest diameter as measured by CT
scan was considered bulky.
Treatment protocol
All patients were treated with the MACOP-B regimen,
given for 12 consecutive weeks, with leucovorin rescue
after any methotrexate-containing cycle. The median
number of cycles delivered was 12. Rituximab was ad-
ministered every 21 days (375 mg/m2) along with
chemotherapy in 57 patients (58.2%), all treated after
2001, when it became available in Italy [7].
Disease restaging, response assessment and survival
analysis
Radiologic restaging was performed by total body CT
scan 1 month after the end of immuno/chemotherapy,
and then 3 months after the completion of RT. PET scan
Table 1 Patients’ subgroups according to the treatment received
Subgroup MACOP-B Rituximab Radiotherapy n(%)
1 Yes No No 11 (11.2%)
2 Yes Yes No 20 (20.4%)
3 Yes Yes Yes 37 (37.8%)
4 Yes No Yes 30 (30.6%)
Total (%) 98 (100%) 57 (58.2%) 67 (68.4%) 98 (100%)
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Bone marrow biopsy was repeated only if positive at
baseline. Treatment responses were categorized accord-
ing to standardized response criteria [17, 18]. Nodal resi-
dues larger than 1.5 cm which have regressed by more
than 75% in their major diameter were compatible with
a complete response (CR), and regarded as residual scar
tissue. PET negativity was corroborative of a CR.
Overall survival (OS) was calculated from diagnosis to
the last follow-up or death for any cause; progression-
free survival (PFS) was calculated from diagnosis to the
first disease progression or death; disease-free survival
(DFS) was determined in all CR patients as the time be-
tween the first documented responses and the first dis-
ease relapse, or death as a result of lymphoma or acute
treatment toxicity. Survival analysis was conducted ac-
cording to Kaplan-Meier’s method and log rank test was
used for comparisons [19]. Demographics and patients’
characteristics were summarized by descriptive statistics
and compared using χ2 test. Statistical analyses were per-
formed with Stata11 (StataCorp LP, TX) and p-values
were set at 0.05.
Results
Patients’ characteristics and disposition
The median age at presentation was 34.5 (range 15.7–
69.5) years; 58 patients were females and 40 males, with
a male-to-female ratio of 1:1.45. Three patients (3.1%)
presented with stage I disease, 68 (69.4%) with stage II, 9
(9.2%) with stage III and 18 (18.4%) with stage IV dis-
ease, with lung, spleen and kidney involvement. B-
symptoms were present in 41 (41.8%) patients; bulky dis-
ease was detected in 95 (96.9%) patients, with a superior
vena cava syndrome in 43 (43.9%) patients.
Sixty-seven (68.4%) patients received mediastinal RT, 4
to 6 weeks after the completion of immuno/chemother-
apy, with tumor doses ranging from 30 to 36 Gy over a
4 to 5 weeks treatment schedule, with fractions of
180 cGy/day for 5 days per week. The decision to use
RT was based on era-specific institutional guidelines: it
was routinely administered after chemotherapy in all pa-
tients since 1993 to 2002; before 1993, it was delivered
upon physician’s discretion; after 2002, along with the
use of PET in detecting potential residual masses after
chemotherapy, RT was spared in those patients with a
negative PET-scan and without bulky disease at onset.
Among the 57 patients who received rituximab, 37
(64.9%) underwent RT, whereas among the 41 who did
not receive rituximab, RT was delivered in 30 (73.2%)
patients. Eleven (11.2%) patients received chemotherapy
only, and 37 (37.8%) received both immunotherapy and
RT. According to the treatment received, patients were
subdivided in 4 subgroups, as outlined in Table 1. Pa-
tients’ clinical characteristics are reported in Table 2.Overall treatment response and survival
After 12 cycles of MACOP-B regimen (with or without
rituximab), 61 patients out of 98 (62.2%) achieved a CR
and 27 (27.6%) a partial response (PR); a stable disease
(SD) was documented in one patient, and 9 showed pro-
gression (PD). Among those who were irradiated after
immuno/chemotherapy, 21 patients previously in PR
could convert their disease status to a CR, with no pa-
tients being with residual disease after RT. Upon com-
pletion of the scheduled treatment, 82 patients achieved
a CR (83.7%) and 6 obtained a PR (6.1%), yielding an
overall response rate (ORR) of 89.8%. At the time of
writing, 73 (88.4%) patients who achieved a CR are still
in continuous CR. Median follow-up duration for the
entire cohort of patients is 7.6 years. The projected OS
at 17 years for all the patients is 72%, with a PFS of
67.6% and a DFS of 88.4%, with all curves showing a
plateau (Fig. 1a-c).
Analysis of response failures
Eleven patients (11.2%) showed a disease relapse or pro-
gression during follow-up, in any case within the first 2
years after treatment completion. Nine patients were in
CR after therapy and 2 in PR. Five received a rituximab-
based treatment and 6 were irradiated. Salvage therapy
for these patients consisted of autologous stem cell
transplantation in all but one cases, with rapid disease
progression and death in 6 of them. The patient who did
not receive any further treatment rapidly died of disease.
Fifteen patients died during follow-up (15.3%), 13 as a
consequence of lymphoma persistence after first-line
treatment or disease relapse or progression. Two pa-
tients died of a secondary neoplasm (colon carcinoma)
both in a CR status and more than 10 years after the
conclusion of the treatment. Although both patients
belonged to subgroup 4, none of the two solid tumors
developed inside a previously irradiated field.
Subgroup analysis
Clinical characteristics across the 4 subgroups were
comparable, with no statistically significant differences
seen at the χ2 test. Overall survival and PFS curves plot-
ted for the four subgroups show a statistically significant
difference (p = 0.0003 and p = 0.0006, respectively),
Table 2 Patients’ characteristics and treatment outcomes according to subgroups
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4
Treatment type
Patients, n
CHT
11
Rituximab + CHT
20
Rituximab + CHT + RT
37
CHT + RT
30
Male: female
Stage I-II
Stage III-IV
B-symptoms
LDH elevation
SVC syndrome
4: 7
5 (45.5%)
6 (54.5%)
7 (63.6%)
5 (45.5%)
7 (63.6%)
7: 13
9 (45.0%)
11 (55.0%)
10 (50.0%)
5 (25.0%)
7 (35.0%)
19: 18
34 (91.9%)
3 (8.1%)
10 (27.0%)
3 (8.1%)
13 (35.1%)
10: 20
23 (76.7%)
7 (23.3%)
14 (46.7%)
12 (40.0%)
16 (53.3%)
ORR
CR
PR
SD
PD
90.9%
6 (54.5%)
4 (36.4%)
1 (9.1%)
0
55.0%
9 (45.0%)
2 (10.0%)
0
9 (45.0%)
100%
37 (100%)
0
0
0
100%
30 (100%)
0
0
0
Relapse/Progress.
Deaths
2 (18.2%)
2 (18.2%)
3 (15.0%)
7 (35.0%)
2 (5.4%)
2 (5.4%)
4 (13.3%)
4 (13.3%)
9 years OS (a)
9 years PFS (a)
5 years DFS
80.0%
63.6%
66.7%
62.3%
45.0%
90.0%
93.6%
94.4%
94.4%
92.2%
86.5%
86.5%
(a) OS and PFS are determined at 6 years for patients in subgroup 2
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terms of DFS (0.2362) (Fig. 1d-f ). However, if OS
curves for subgroup 1 and 2 are taken together – i.e.
considering patients treated with chemotherapy or
chemo + immunotherapy without any RT consolidation
– no statistically significant difference can be detected
(p = 0.0806), thus the discrepancy between these data
does not depend either on patients’ selection or on par-
ticularly unfavorable clinical characteristics of patients
in subgroup 2.Fig. 1 Overall survival (a), progression-free survival (b) and disease-free surv
survival analysis is shown underneath: overall survival (d), progression-free sur
dashed black line is for subgroup 2, solid grey line is for subgroup 3 and dasheAll the patients receiving RT – as a consolidation
strategy after they had obtained either a CR or a PR –
showed an ORR of 100%, with no residual disease being
detectable after radiation. This favorable result can be
appreciated both in patients receiving rituximab (sub-
group 3) and in those with no exposure to the antibody
(subgroup 4), with comparable OS rates in the two sub-
groups at 9 years (p = 0.5103).
DFS rates between subgroup 2 and 3 do not signifi-
cantly differ (p = 0.55), although the number of patientsival (c) curves plotted for the entire population on study. Subgroup
vival (e) and disease-free survival (f). Solid black line is for subgroup 1,
d black line is for subgroup 4. Vertical axis shows survival percentages
Broccoli et al. BMC Cancer  (2017) 17:276 Page 5 of 8in CR after treatment is substantially different. This indi-
cates that patients in CR after chemo + immunotherapy
behave similarly to those who achieve a CR after receiv-
ing mediastinal RT, suggesting that RT has a small con-
solidative potential in those who obtain a CR status after
chemo-immunotherapy only.
Role of rituximab
When patients are subdivided according to whether they
have received rituximab or not (Table 3), regardless a
subsequent consolidative RT, no statistically significant
differences in terms of OS and DFS (p = 0.1 and 0.19,
respectively) can be observed (Fig. 2), thus indicating
that the addition of the anti-CD20 monoclonal seems to
have a limited impact on patients’ survival in our study
population. Of note, however, a more favorable trend to
better PFS and DFS is observed in those belonging to
subgroup 3 compared to patients in subgroup 4, the
former also receiving rituximab together with chemo-
therapy and RT consolidation.
Discussion
The clinical and pathological peculiarities of PMLBCL,
the high chances of cure documented in literature in
more than 20 years of international experience and the
long disease-free life-expectancy of cured patients, have
always drawn attention in finding out the most suitable
first-line approach and the most convenient combination
of treatment modalities, on the one hand trying to
maximize the long-term clinical outcomes, while on the
other reducing the potential harmful consequences of
highly toxic combined treatments [20, 21].
Our monocentric experience over a period of more
than 20 years ideally encompasses all the issues met by
treating physicians throughout the years, and may virtu-
ally suggest some still open points which require clarifi-
cation with further ad hoc studies. It consists of a seriesTable 3 Patients’ characteristics and treatment outcomes
according to exposure to rituximab
CHT ± RT R + CHT ± RT
Patients, n 41 57
Male: female
Stage I-II
Stage III-IV
B-symptoms
LDH elevation
SVC syndrome
14: 27
28 (68.3%)
13 (31.7%)
21 (51.2%)
17 (41.5%)
23 (56.1%)
26: 31
43 (75.4%)
14 (24.6%)
20 (35.1%)
8 (14.0%)
20 (35.1%)
ORR
CR
PR
SD
PD
97.6%
36 (87.8%)
4 (9.8%)
1 (2.4%)
0
84.2%
46 (80.7%)
2 (3.5%)
0
9 (15.8%)
9 years OS
9 years DFS
89.0%
83.2%
83.1%
93.5%of 98 patients homogeneously treated with a weekly
“third-generation” schedule, who in part also received ex-
ternal mediastinal RT and/or anti-CD 20 immunotherapy,
depending on our institutional era-specific guidelines.
“Third-generation” regimens, have become the stand-
ard of treatment in many European institutions, follow-
ing the favorable results obtained when compared with
the standard CHOP regimen. Lazzarino et al. docu-
mented MACOP-B/VACOP-B superiority on CHOP
both in terms of CR rates and relapse-free survival
(RFS), with 73% CR rate for the former versus 36% for
the latter, and a 3-years RFS of 58% versus 38% [22, 23].
A retrospective multicenter Italian experience on 138
patients appeared later again emphasized the difference
between the two regimens: patients on MACOP-B/
VACOP-B achieved better results than those on CHOP,
in terms of complete responses and event-free survival
(EFS) rates, with statistically significant difference in low
and low-intermediate International Prognostic Index risk
groups (into which the majority of patients with PMLBCL
generally fall), whereas lacking significance in high-
intermediate and high-risk disease [6, 24].
The role of the anti-CD20 monoclonal antibody, ritux-
imab, in a context of a chemo-immunotherapy regimen,
still represents a matter of debate: its role in patients
with PMLBCL is less well established than in DLBCL,
and most of available data derive from retrospective ex-
periences and do not rely on appropriately powered ran-
domized trials. On the one hand, rituximab added to
CHOP has demonstrated better EFS and OS rates than
CHOP alone (80% and 89% versus 47% and 69% at
5 years, respectively), as well as higher complete re-
sponse rates and a significant reduction of disease pro-
gression [12, 13, 21]. However, in a study from British
Columbia, a comparison of rituximab-CHOP and CHOP
alone in PMLBCL patients has failed to show any clear
survival advantage of the former regimen [25]; moreover,
patients treated with MACOP-B/VACOP-B within the
same institution showed superior outcomes over CHOP-
type treatments, in terms of OS (87%, 82% and 71% for
patients treated with M[V]ACOP-B, rituximab-CHOP
and CHOP, respectively). Data from a recent experience
have also shown that in a subset of 63 PMLBCL patients
treated with rituximab-CHOP, with or without radiation,
a primary induction failure unacceptably occurred in
21% of the treated patients, particularly in those with in-
creased IPI score, advanced age and stage or multiple
extranodal localizations [21, 26].
A multicenter Italian experience has demonstrated that
the combination of rituximab with a “third-generation”
regimen is not significantly different from rituximab-
CHOP, rituximab-EPOCH (etoposide, doxorubicin, cyclo-
phosphamide, vincristine, prednisone) or M[V]ACOP-B
therapy alone in terms of EFS: this means that the
Fig. 2 Overall survival (a) and disease-free survival (b) curves plotted according to the administration of rituximab with chemotherapy. Vertical axis
shows survival percentages. R rituximab; CHT chemotherapy
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like regimen is used as induction therapy, but it confers
little benefit if it is added to a more intense treatment
strategy [11]. Data from our series indicate no substantial
improvement from the addition of rituximab to MACOP-
B (subgroups 1 and 2, Table 3 and Fig. 2) in terms of OS
(p = 0.0806 between subgroups 1 and 2; p = 0.10 between
R-MACOP-B and MACOP-B only). The better OS and
PFS outcomes seen in subgroups 3 and 4, therefore, pre-
sumably rely more on the use of RT than of rituximab.
It is clear, in fact, that external mediastinal RT, deliv-
ered after immuno/chemotherapy as a consolidative
strategy, still impacts markedly on global survival and on
CR rates, being able to convert PRs to CRs in the major-
ity of cases [6, 14, 27]. In a retrospective multinational
study on 426 untreated patients, data from patients
treated with CHOP/CHOP-like, M[V]ACOP-B regimens
and high-dose therapy/autotransplantation were com-
pared: CR rates obtained upon completion of the three
chemotherapy arms were similar (49%, 51% and 53%, re-
spectively), but they significantly differed after medias-
tinal RT (67%, 84% and 77%, respectively) and in terms
of 10-years OS (44%, 71% and 77%, respectively) and
PFS (35%, 67% and 78%, respectively) [28].
Concerns exist, however, regarding the incidence of
second malignancies and late side effects after chest ir-
radiation, mainly on the cardiovascular system [29–31]:
risks and benefits should be thoroughly balanced at the
moment of treatment planning, although more experi-
ence is required in identifying patients in whom RT can
be spared. Dunleavy et al. have recently demonstrated
that the use of a dose-adjusted chemotherapy based on
EPOCH and containing rituximab could obviate the
need for radiotherapy in PMLBCL patients, with EFS
and OS rates of 93% and 97%, respectively, and no re-
lapsing patients over a median follow-up of more than
5 years [32]. However, a post-chemotherapy PET evalu-
ation may represent a tool to guide the RT usage, rea-
sonably sparing mediastinal irradiation in those who
show a PET-negativity – i.e. Deauville score 1–2, andpossibly 3 – after the completion of the chemo/im-
munotherapy induction [21, 33, 34]. Data in this sense
are from Savage et al., where the PET-guided RT ap-
proach was applied in rituximab-CHOP-treated patients
[35]. Similarly, we have recently published an experience
from our institution involving 74 patients – belonging to
an independent data base from the one we have de-
scribed in this paper – all treated with a rituximab-
MACOP-B induction therapy [36]. In both reported
series, patients with a PET-documented CR were ob-
served, whereas those with a positive PET-scan received
consolidative RT [35, 36]. OS and time-to-progression
seen in the first series were 89% and 83% at 5 years, re-
spectively, whereas in our recent experience OS and
DFS rates were 82% and 91% at 10 years, respectively,
without any significant difference between irradiated and
not-irradiated patients [35, 36]. A similar trend can be
appreciated after comparing the DFS rates for subgroups
2 and 3 in the present study (90.0% and 94.4%, respect-
ively, at 5 years, p = 0.55).
PET functional parameters measured at disease diag-
nosis may also represent useful tools in order to deter-
mine which patients will do worse with standard
treatment schedules, therefore requiring a more intense
approach since the beginning [37]. In addition, the de-
tection of a truncating deletion of the NFKBIE gene,
which encodes IκBε, a negative feedback regulator of
NF-κB, and which is frequently observed in PMLBCL
patients, may help segregate patients with a more ag-
gressive disease and with therapy refractoriness [38]. It
has been demonstrated that NFKBIE-deleted patients, in
fact, display inferior outcomes compared to wild-type
ones, but apparently benefit greatly from RT and rituxi-
mab [38].
Conclusions
In conclusion, data we have gathered over a 20-year ex-
perience in the treatment of PMLBCL patients clearly
indicate that: 1) a “third-generation” chemotherapy regi-
men such as MACOP-B is feasible and easily deliverable
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ference is seen in our series between those who received
rituximab and those who did not, although a trend to
better DFS rates is appreciated in patients treated with
chemo + immunotherapy and RT; 3) radiotherapy in this
context remains a powerful strategy to convert PRs to
CRs, but it may be spared in patients obtaining a PET-
documented CR after chemo-immunotherapy without
any harmful prognostic consequences. Hopefully, future
prospective trials – such as the ongoing International
Extranodal Lymphoma Study Group 37 study – will fur-
ther investigate the role of consolidation radiation ther-
apy in PET-negative patients after induction treatment.
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